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Abstract
Background: The World Health Organization reported in 2007 that inclusion of PCV7 in national immunization
programs should be seen as a priority, also encouraging countries to conduct appropriate surveillances for
monitoring the impact of vaccination. These analyses should be conducted in specific geographical areas and
should be aimed to evolution of invasive pneumococcal disease (IPD), by age groups, clinical presentation, and
vaccine serotypes (and non-vaccine serotypes to detect possible replacement). This study aimed to monitor the
evolution of IPD incidence in children <15 years requiring hospitalization in the Island of Majorca.
Methods: A prospective clinical surveillance of all culture and/or PCR-confirmed IPD in children <15 years was
performed in all hospitals in the Island of Majorca (approximately 900,000 inhabitants) from January 2008 to
December 2010. Incidence rate (IR) was calculated as cases/100000 inhabitants using children population data.
Results: 66 IPDs were identified: 39 (59.1%) parapneumonic pneumococcal empyema (PPE), 16 (24.2%) bacteremic
pneumonia (BP), 7 (10.6%) primary bacteremia, 3 (4.5%) meningitis, and 1 (1.5%) osteomyelitis. IRs in the three-year
study period were: 64.22 for children 12- < 24 months, 37.21 for those 24-59 months, 22.62 for those <12 months,
and 3.98 for children >59 months. By study year, IRs were 21.25 in 2008, 19.89 in 2009 and 9.80 in 2010. The
reduction found in 2010 was significant and due to significant reductions in IRs of IPDs caused by serotypes
included in PCV10 and PCV13. Overall, estimated serotype coverage by conjugate vaccines was 12.1% for PCV7,
37.9% for PCV10 and 65.2% for PCV13. Of the 66 hospitalized children with IPD, 20 had received at least one dose
of PCV7 (13 cases with identified serotype). None of these 13 cases was caused by PCV7 serotypes, all were caused
by PCV13 serotypes and only 53.8% by PCV10 serotypes.
Conclusions: The results of the present study evidence the importance of expanding the number of serotypes
covered by PCV, and the added value of PCV13 with respect to PCV10 and PCV7, even in an area of low prevalence
of 19A as the Island of Majorca.
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Background
Pneumococcal conjugate vaccines (PCV) provide serotype-
specific protection, reduced carriage of vaccine-related se-
rotypes that are often antibiotic-resistant, in the vaccinated
individual as well as in the population at large through herd
immunity [1]. While the use of the 7-valent PCV (PCV7)
has been very effective in reducing invasive pneumococcal
disease (IPD), particularly in children under two years in
the USA, the impact in Europe is less certain as vaccination
programs differ in individual member states [2]. The World
Health Organization reported in 2007 that inclusion of
PCV7 in national immunization programs should be seen
as a priority, also encouraging countries to conduct appro-
priate surveillances for monitoring the impact of vac-
cination [3]. These analyses should be conducted in
specific geographical areas and should be aimed to evo-
lution of IPD, by age groups, clinical presentation, and
vaccine serotypes (and non-vaccine serotypes to detect
possible replacement).
In order to improve vaccine protection, vaccination
with new PCV with increased serotype coverage has
been proposed. PCV7 (including serotypes 4, 6B, 9V, 14,
18C, 19F and 23F) was introduced in Spain in June
2001. In November 2009 the 10-valent PCV (PCV10)
including as new serotypes (in addition to those included
in PCV7) serotypes 1, 5 and 7F was licensed in our coun-
try, and in June 2010 the 13-valent PCV (PCV13) was li-
censed with the goal of expanding serotype coverage by
including, in addition to serotypes present in PCV10, sero-
types 3, 6A and 19A. The three PCV were licensed for
healthy children immunization and are available in Spain
only in the private market except in the Autonomous Re-
gion of Madrid that approved inclusion of PCV7 in the
childhood vaccination calendar in October 2006, with a
switch to PCV13 in 2010, and Galicia that included
PCV13 in the vaccination calendar in 2011.
The aim of this study was to monitor the evolution of
IPD incidence in children requiring hospitalization in
the Island of Majorca over a 3-year period (2008-2010),
with analysis by age, serotype and clinical presentation.
Methods
A prospective, hospital-based active surveillance study on
IPD was carried out in all three hospitals with pediatric de-
partment located in the island of Majorca (approximately
900,000 inhabitants), Spain, all over 3 years (January 2008 -
December 2010). The study population consisted in all hos-
pitalized children (<15 years old) with laboratory confirmed
IPD by culture and/or PCR. IPD was defined as presence of
S. pneumoniae, by culture and/or PCR, in normal sterile
fluids as blood, pleural fluid and cerebrospinal fluid. Writ-
ten informed consent for participation in the study was ob-
tained from parents/guardians. The Ethical Committee of
the Illes Balears approved the study (IB881/07).
Basic demographic data (age, gender, PCV7 vaccination
status) and clinical presentation were recorded. Samples
were sent to the clinical microbiology laboratory at each
center for microbiological culture and/or PCR detection.
All pneumococcal isolates were sent to a single reference
laboratory (Microbiology Dpt. of the Universitary Clinic
Hospital in Madrid) for serotyping by Quellung reaction.
Pleural and cerebrospinal fluids not yielding positive cul-
ture were also sent to the reference laboratory for being
analyzed by PCR for pneumolysin (ply) and autolysin (lyt)
genes [4,5]. Pneumococci confirmed by PCR were sero-
typed using a real-time PCR assay [6]. Susceptibility to
penicillin, cefotaxime and erythromycin was determined
by microdilution following CLSI recommendations [7].
Current CLSI breakpoints [8] were considered for suscep-
tibility interpretation.
The macrolide resistance phenotypes were determined
by the double disc diffusion method with erythromycin
(15 μg) and clindamycin (2 μg) discs on Mueller-Hinton
agar supplemented with 5% sheep blood. The plates were
incubated overnight in 5% CO2 atmosphere at 35°C. The
erm(B) and mef(A/E) genes were detected by PCR [9],
with a subsequent PCR to differentiate between mef(A)
and mef(E) genes [10].
Incidence rates (IRs) were calculated as the number of
cases per 100 000 inhabitants using population data on
children in Majorca (for each study period, for age groups
and for total number of children ≤15 years of age) from
Instituto Nacional de Estadistica [11]. Vaccine doses dis-
position data were obtained from IMS (Intercontinental
Marketing Services Iberica S.A., Madrid, Spain). Per-year
the estimated population covered by the vaccine was cal-
culated by ascertaining both the population target for vac-
cination (children <24 months) and the estimated number
of complete vaccination schedules (primary vaccination -3
doses- and the booster dose) from the number of vaccine
doses sold in Majorca. Comparisons of IRs were per-
formed with the EPIDAT version 3.1.
Results
The number of doses of conjugate vaccines sold in Majorca
was 20228 (100% PCV7) in 2008, 19986 (100% PCV7) in
2009, and 50243 (24.8% PCV7, 41.3% PCV10 and 33.9%
PCV13) in 2010. The estimated target population
(<24 months) covered by vaccination was 27.7% in
2008, 26.2% in 2009 and 66.8% in 2010.
A total of 66 IPDs were identified in the study period: 39
(59.1%) parapneumonic pneumococcal empyema (PPE), 16
(24.2%) bacteremic pneumonia (BP), 7 (10.6%) primary
bacteremia, 3 (4.5%) meningitis, and 1 (1.5%) osteomyelitis.
Mean age was 36.8 ± 26.5 months and 51.5% were males.
Mean length of hospitalization was 16.3 days, with 21.5%
patients requiring ICU admission. Up to 92.4% children re-
covered without sequelae, 6.1% with sequelae, and mortality
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was 1.5% (a 23-month non-vaccinated child with PPE).
Table 1 shows incidence rates of IPDs, and of PPE and BP
in the total pediatric population (children <15 years) by
study year. Significant (p < 0.05) lower IRs of IPDs were
found in 2010 compared with previous years, with a reduc-
tion of 53.9% compared to IRs in 2008 and 50.7% compared
to 2009. These reductions were due to significant (p < 0.01)
reductions in IRs of IPDs caused by serotypes included in
PCV10 and PCV13. Incidence of PPE also decreased in
2010 (reduction of 38.4% of IRs compared to 2008 and of
44.5% of IRs compared to 2009), but reductions did not
reach statistical significance. Although reductions in IRs of
BP in 2010 (reduction of 76.0% of IRs compared to 2008
and of 67.1% compared to 2009) were also non-significant,
significant decreases (p < 0.05) were found in BPs by
PCV10 and by PCV13 between 2008 and 2010.
Table 2 shows by study year IRs of IPDs in the different
age groups (<12 months, 12- < 24 months, 24-59 months
and >59 months). In the population target for vaccination
(children <24 months), IRs were 49.29 in 2008, 52.52 in
2009 and 31.90 in 2010. By age group, the highest inci-
dence was found in the group of 12- < 24 months (IR =
64.22) followed by the group of 24-59 months (IR = 37.21)
and the group of children <12 months (IR = 22.62), with
an incidence of only 3.98 per 100 000 inhabitants among
children >59 months in the 3-year study period. While
there was a non-significant increase in IRs in 2010 in chil-
dren <12 months, there was a decrease in the remaining
age groups. In the group of children 12- < 24 months, the
reduction in IRs in 2010 vs. 2009 (79.5% reduction)
reached statistical significance.
The responsible serotype could be identified in 48 out of
the 66 cases by the method used, with 18 non-typeable
pneumococci. Serotype 1 was the most frequent (n = 11)
followed by serotype 3 (n = 8), 7F (n = 6), 19A (n = 5), 14
(n = 4), serotypes 12 and 19F (2 isolates each), serotypes
6A, 6B, 13, 23F, 25A, 33B (1 isolate each) and serogroup 6
(n = 4). The estimated PCV coverage was: 12.1% for
PCV7, 37.9% for PCV10 and 65.2% for PCV13. Of the 66
IPDs, 36 cases were confirmed by culture and 30 only by
PCR. Of the 36 isolates, 31 were recovered for susceptibil-
ity testing at the central laboratory. Of the 31 isolates, two
came from non-vaccinated patients with meningitis: one
serotype 23B isolated in a <12 months infant and one sero-
type 14 from a child aged 12- < 24 months, both isolates
susceptible to penicillin and cefotaxime. The 29 remaining
isolates (causing non meninigitis IPDs) belonged to
Table 1 By study year, number and incidence rates (IR) of
total IPD, total PPE (parapneumonic pneumococcal
empyema) and total BP (bacteremic pneumonia), and
number and IR of those caused by serotypes included in
PCV7, PCV10 and PCV13
2008 2009 2010 Total
Population ≤15 years 127041 130703 132632 390376
n (IR) n (IR) n (IR) n (IR)
IPDs 27 (21.25) 26 (19.89) 13 (9.80)a,b 66c (16.91)
PCV7-IPDs 4 (3.15) 3 (2.30) 1 (0.75) 8 (2.05)
PCV10-IPDs 17 (13.38) 7 (5.36) 1 (0.75)a 25 (6.40)
PCV13-IPDs 22 (17.32) 14 (10.71) 7 (5.28)a 43 (11.02)
PPE 14 (11.02) 16 (12.24) 9 (6.79) 39 (9.99)
PPE by PCV7 1 (0.79) 0 (0.00) 0 (0.00) 1 (0.26)
PPE by PCV10 6 (4.72) 3 (2.30) 0 (0.00) 9 (2.31)
PPE by PCV13 11 (8.66) 7 (5.36) 4 (3.02) 22 (5.64)
BP 8 (6.30) 6 (4.59) 2 (1.51) 16 (4.10)
BP by PCV7 0 (0.00) 1 (0.77) 1 (0.75) 2 (0.51)
BP by PCV10 8 (6.30) 2 (1.53) 1 (0.75)a 11 (2.82)
BP by PCV13 8 (6.30) 4 (3.06) 1 (0.75)a 13 (3.33)
ap ≤ 0.05 vs. 2008.
bp ≤ 0.05 vs. 2009.
cIncludes 39 PPE, 16 BP, 7 primary bacteremia, 3 meningitis and
1 osteomyelitis.
Table 2 By study year, number and incidence rates by
age group of total IPDs and of those caused by serotypes
included in PCV7, PCV10 and PCV13
2008 2009 2010 Total
<12 months
Population 8587 9484 8450 26521
n (IR) n (IR) n (IR) n (IR)
IPD 1 (11.65) 1 (10.54) 4 (47.34) 6 (22.62)
PCV7-IPDs 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00)
PCV10-IPDs 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00)
PCV13-IPDs 0 (0.00) 0 (0.00) 2 (23.67) 2 (7.54)
12- < 24 months
Population 9672 9556 10358 29586
IPD 8 (82.71) 9 (94.18) 2 (19.31)a 19 (64.22)
PCV7-IPDs 3 (31.02) 2 (20.93) 0 (0.00) 5 (16.90)
PCV10-IPDs 4 (41.36) 2 (20.93) 0 (0.00) 6 (20.28)
PCV13-IPDs 6 (62.03) 4 (41.86) 2 (19.31) 12 (40.46)
24-59 months
Population 26984 28011 28318 83313
IPD 12 (44.47) 12 (42.84) 7 (24.72) 31 (37.21)
PCV7-IPDs 1 (3.71) 1 (3.57) 1 (3.53) 3 (3.60)
PCV10-IPDs 9 (33.35) 3 (10.71) 1 (3.53) 13 (15.60)
PCV13-IPDs 11 (40.76) 7 (24.99) 3 (10.59) 21 (25.21)
>59 months
Population 81798 83652 85506 250956
IPD 6 (7.34) 4 (4.78) 0 (0.00) 10 (3.98)
PCV7-IPDs 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00)
PCV10-IPDs 4 (4.89) 2 (2.39) 0 (0.00) 6 (2.39)
PCV13-IPDs 5 (6.11) 3 (3.59) 0 (0.00) 8 (3.19)
ap ≤ 0.05 vs. 2009.
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serotype 1 (n = 8), 7F (n = 5), 19A (n = 5), 14 (n = 3), 19F
(n = 2) and six different serotypes (one isolate each). Seven
isolates were fully resistant to erythromycin: four 19A iso-
lates (3 ermB/mefE and one ermB), two serogroup 6 (erm
B) and one serotype 19F (erm B/mefA). The serotype 19F
isolate showed also intermediate resistance to penicillin
and one of the serogroup 6 isolates also showed intermedi-
ate resistance to penicillin and cefotaxime. In addition two
serotype 14 isolates showed intermediate resistance to
penicillin and cefotaxime and one serotype 13 isolate
showed intermediate resistance to penicillin.
Of the identified 66 children with IPD, 20 had received
at least one dose of PCV7 (2 children only one dose, 5
children two doses, 11 children three doses and 2 children
four doses). The serotype causing the IPD was identified
in 13 out of these 20 children. None of the cases was
caused by a serotype included in PCV7. Seven cases were
caused by new serotypes in PCV10 (serotype 1 in 5 cases
and 7F in 2 cases) and the remaining 6 cases by serotypes
exclusively included in PCV13 (serotype 3 in 4 cases, and
serotypes 6A and 19A in one case each).
Discussion
The introduction of PCV7 has resulted in a marked reduc-
tion in rates of IPD by vaccine types [1]. The magnitude of
the reductions is related to the prevalence of vaccine sero-
types in the pre-vaccination era and to the modest in-
crease in rates of IPDs by non-vaccine serotypes [12,13].
The present study was carried out in an area where PCV
were not included in the childhood vaccination calendar,
and the estimated coverage of the target population was
low in 2008 and 2009 (≈27%) but highly increased to ≈
67% in 2010 after the launch of PCV10 and PCV13. This
could be related with a significant decrease in IPDs in
2010, mainly due to the decrease in IPDs by PCV10
and PCV13 serotypes, primarily occurring in children
aged 12- < 24 months. This is in accordance with data
from the HERACLES study in Madrid where, 11 months
after the switch from PCV7 to PCV13 in the vaccination
calendar, a decline in incidence rates of IPDs was observed
in children <15 years of age mainly due to reductions in
the age group of 12- < 24 months and in IPDs by serotype
1 and 19A [14,15].
Previous published data from our country indicated
the need for expanding the coverage provided by PCV7
since among IPD cases described in a study carried out
in Catalonia in 2009, 12.2% were caused by PCV7 sero-
types, 51% by PCV10 serotypes, and 71.1% by PCV13 sero-
types [16]. In another study in Barcelona (2007-09), 91%
IPDs were caused by non-PCV7 serotypes, with serotypes
1, 19A and 3 as the most frequent [17]. The importance of
non-PCV7 serotypes was also evidenced by analyzing data
from areas, as Madrid, with PCV7 in the vaccination
calendar, since after universal vaccination non-PCV7 sero-
types caused 95.5% IPDs [18]. In the present study, the esti-
mated serotype coverage by the different PCV greatly
increased by increasing the number of serotypes included.
None of the children that had received at least one PCV7
dose had an IPD caused by PVC7 serotypes, and among
vaccinated children, all cases with identified serotype were
caused by serotypes included in PCV13 and only 53.8% by
serotypes covered by PCV10. All these facts evidence the
importance of expanding the number of serotypes covered
by PCV, and the added value of PCV13 (mainly by includ-
ing serotypes 3 and 19A) with respect to PCV10 and
PCV7. This importance would be even higher in other
areas of our country where 19A is highly prevalent [18-20].
IPDs caused by serotype 19A were not found in a previous
study in 2003-4 in Majorca [21], and in our series they only
represented 7.6% of all IPDs. Probably a low prevalence of
serotype 19A in Majorca made this serotype non-selectable
by PCV7 use.
IRs of IPDs found in 2008 and 2009 in the present study
in children <24 months were similar to the one previously
reported in Majorca in 2003 [21]. Although the number of
IPDs described in the present series is limited, thus com-
promising comparisons when dividing the population by
clinical presentation or age group, the study included all
pediatric IPDs requiring hospitalization over three years in
Majorca, the largest of the Balearic Islands located in the
Western Mediterranean sea.
The reduction in IRs of IPDs shown in the present study
in 2010 in the total pediatric population and in children
aged 12- < 24 months will probably be greater in the next
years since it has been postulated that 2-3 years of univer-
sal vaccination are necessary before disease rates stabilize
and higher decreases compared to baseline are shown
[1,12,13], and second-generation PCVs are increasingly
being used in Majorca. In this sense, decision analytic
models evaluating health and economic outcomes have
shown that universal PCV13 vaccination would be a cost-
effective intervention in other areas of Spain as Valencia
or of Europe as Switzerland [22,23].
Conclusions
The results of the present study evidence the importance
of expanding the number of serotypes covered by PCV,
and the added value of PCV13 with respect to PCV10 and
PCV7, even in an area of low prevalence of 19A as the
island of Majorca.
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